Page 65 - Read Online

Estévez-Arias et al. J Transl Genet Genom 2022;6:333-52 https://dx.doi.org/10.20517/jtgg.2022.04 Page 349

34. Jani-Acsadi A, Krajewski K, Shy ME. Charcot-Marie-Tooth neuropathies: diagnosis and management. Semin Neurol 2008;28:185-
94. DOI PubMed
35. Burns J, Crosbie J, Ouvrier R, Hunt A. Effective orthotic therapy for the painful cavus foot: a randomized controlled trial. J Am
Podiatr Med Assoc 2006;96:205-11. DOI PubMed
36. Piscosquito G, Reilly MM, Schenone A, et al; CMT-TRIAAL & CMT-TRAUK Group. Is overwork weakness relevant in Charcot-
Marie-Tooth disease? J Neurol Neurosurg Psychiatry 2014;85:1354-8. DOI PubMed
37. Beals TC, Nickisch F. Charcot-Marie-Tooth disease and the cavovarus foot. Foot Ankle Clin 2008;13:259-74. DOI PubMed
38. Shy ME. Therapeutic strategies for the inherited neuropathies. Neuromol Med 2006;8:255-78. DOI PubMed
39. Herrmann DN. Experimental therapeutics in hereditary neuropathies: the past, the present, and the future. Neurotherapeutics
2008;5:507-15. DOI PubMed PMC
40. zu Horste G, Prukop T, Liebetanz D, Mobius W, Nave KA, Sereda MW. Antiprogesterone therapy uncouples axonal loss from
demyelination in a transgenic rat model of CMT1A neuropathy. Ann Neurol 2007;61:61-72. DOI
41. Sahenk Z, Nagaraja HN, McCracken BS, et al. NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse
models and in patients. Neurology 2005;65:681-9. DOI PubMed
42. Passage E, Norreel JC, Noack-Fraissignes P, et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-
Marie-Tooth disease. Nat Med 2004;10:396-401. DOI PubMed
43. Singh S. From exotic spice to modern drug? Cell 2007;130:765-8. DOI PubMed
44. Gess B, Baets J, De Jonghe P, Reilly MM, Pareyson D, Young P. Ascorbic acid for the treatment of Charcot-Marie-Tooth disease.
Cochrane Database Syst Rev 2015;12:CD011952. DOI PubMed PMC
45. Sereda MW, Meyer zu Hörste G, Suter U, Uzma N, Nave KA. Therapeutic administration of progesterone antagonist in a model of
Charcot-Marie-Tooth disease (CMT-1A). Nat Med 2003;9:1533-7. DOI PubMed
46. Attarian S, Young P, Brannagan TH, et al. A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of
Charcot-Marie-Tooth type 1A. Orphanet J Rare Dis 2021;16:433. DOI PubMed PMC
47. d'Ydewalle C, Krishnan J, Chiheb DM, et al. HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced
Charcot-Marie-Tooth disease. Nat Med 2011;17:968-74. DOI PubMed
48. Adalbert R, Kaieda A, Antoniou C, et al. Novel HDAC6 Inhibitors increase tubulin acetylation and rescue axonal transport of
mitochondria in a model of Charcot-Marie-Tooth type 2F. ACS Chem Neurosci 2020;11:258-67. DOI PubMed
49. Picci C, Wong VSC, Costa CJ, et al. HDAC6 inhibition promotes α-tubulin acetylation and ameliorates CMT2A peripheral
neuropathy in mice. Exp Neurol 2020;328:113281. DOI PubMed
50. Pisciotta C, Saveri P, Pareyson D. Challenges in treating Charcot-Marie-Tooth disease and related neuropathies: current management
and future perspectives. Brain Sci 2021;11:1447. DOI PubMed PMC
51. Rossaert E, Van Den Bosch L. HDAC6 inhibitors: translating genetic and molecular insights into a therapy for axonal CMT. Brain
Res 2020;1733:146692. DOI PubMed
52. Nuevo-Tapioles C, Santacatterina F, Sánchez-Garrido B, et al. Effective therapeutic strategies in a preclinical mouse model of
Charcot-Marie-Tooth disease. Hum Mol Genet 2021;30:2441-55. DOI PubMed PMC
53. Kagiava A, Karaiskos C, Richter J, et al. AAV9-mediated schwann cell-targeted gene therapy rescues a model of demyelinating
neuropathy. Gene Ther 2021;28:659-75. DOI PubMed PMC
54. Marco A, Cuesta A, Pedrola L, Palau F, Marín I. Evolutionary and structural analyses of GDAP1, involved in Charcot-Marie-Tooth
disease, characterize a novel class of glutathione transferase-related genes. Mol Biol Evol 2004;21:176-87. DOI PubMed
55. Huber N, Bieniossek C, Wagner KM, et al. Glutathione-conjugating and membrane-remodeling activity of GDAP1 relies on
amphipathic C-terminal domain. Sci Rep 2016;6:36930. DOI PubMed PMC
56. Chen CX, Li JQ, Dong HL, Liu GL, Bai G, Wu ZY. Identification and functional characterization of novel GDAP1 variants in
Chinese patients with Charcot-Marie-Tooth disease. Ann Clin Transl Neurol 2020;7:2381-92. DOI PubMed PMC
57. Niemann A, Ruegg M, La Padula V, Schenone A, Suter U. Ganglioside-induced differentiation associated protein 1 is a regulator of
the mitochondrial network: new implications for Charcot-Marie-Tooth disease. J Cell Biol 2005;170:1067-78. DOI PubMed PMC
58. Pedrola L, Espert A, Valdés-Sánchez T, et al. Cell expression of GDAP1 in the nervous system and pathogenesis of Charcot-Marie-
Tooth type 4A disease. J Cell Mol Med 2008;12:679-89. DOI PubMed PMC
59. Binięda K, Rzepnikowska W, Kolakowski D, et al. Mutations in. GDAP1 2018;22:914. DOI PubMed PMC
60. Azzedine H, Ruberg M, Ente D, et al. Variability of disease progression in a family with autosomal recessive CMT associated with a
S194X and new R310Q mutation in the GDAP1 gene. Neuromuscul Disord 2003;13:341-6. PubMed
61. Manganelli F, Pisciotta C, Nolano M, et al. A novel autosomal dominant GDAP1 mutation in an Italian CMT2 family. J Peripher
Nerv Syst 2012;17:351-5. DOI PubMed
62. Cantarero L, Juárez-Escoto E, Civera-Tregón A, et al. Mitochondria-lysosome membrane contacts are defective in GDAP1-related
Charcot-Marie-Tooth disease. Hum Mol Genet 2021;29:3589-605. DOI PubMed PMC
63. Sevilla T, Cuesta A, Chumillas MJ, et al. Clinical, electrophysiological and morphological findings of Charcot-Marie-Tooth
neuropathy with vocal cord palsy and mutations in the GDAP1 gene. Brain 2003;126:2023-33. DOI PubMed
64. Niemann A, Wagner KM, Ruegg M, Suter U. GDAP1 mutations differ in their effects on mitochondrial dynamics and apoptosis
depending on the mode of inheritance. Neurobiol Dis 2009;36:509-20. DOI PubMed
65. Noack R, Frede S, Albrecht P, et al. Charcot-Marie-Tooth disease CMT4A: GDAP1 increases cellular glutathione and the